The EU's drugs regulator said it would review a conditional approval application for AstraZeneca and Oxford University's Covid-19 vaccine this month under an accelerated timeline.
EMA justified its upcoming move by saying that the fast-track evaluation is possible as it has "already reviewed some data on the vaccine" during a meeting of its scientific committee for human medicines (CHMP), given that the condition that the data submitted by AstraZeneca/Oxford "are sufficiently robust and complete".
The agency said it would conduct an expedited review, with a decision that could be made on January 29, if the data reported is "robust and complete" enough.More news: Everton's Calvert-Lewin to miss Wolves trip with injury: Ancelotti
European Commission President Ursula von der Leyen described this as "good news" on Twitter.
The European Union and EMA are under pressure to speed up approval of new vaccines against the virus, which has already claimed more than 620,000 lives across the continent.
Australia has invested in a range of different vaccines, but the AstraZeneca recipe stands at the forefront of the nation's rollout plans.
The AstraZeneca COVID-19 vaccine requires two doses for it to be effective.More news: Photos of free school meal packages in the United Kingdom spark outrage online
The Caloocan City government signed an agreement with British-Swedish pharmaceutical company AstraZeneca for the purchase of 600,000 coronavirus disease-2019 (COVID-19) vaccines that will be distributed for free to the city's residents.
It has, however, been the subject of criticism due to confusion in interim results from clinical trials.
Switzerland approved the Moderna vaccine yesterday.
An 82-year-old man became the first person in the world to receive the Oxford-AstraZeneca jab as the United Kingdom rolled out the vaccine as part of its inoculation program earlier this month.More news: What is Parler and why has it been pulled offline?
The company has said it will sell it for $2.50 (€2) a dose. It is also studying additional information provided by AstraZeneca at the CHMP's request.